Document Type : Original Research


1 Department of Pathology, Pathology and Stem Cells Research Center, Afzali Pour Medical Faculty, Kerman University of Medical Sciences, Kerman, Iran

2 Department of Basic Sciences, Faculty of Veterinary Medicine, Shahid Bahonar University of Kerman, Kerman, Iran

3 Legal Medicine Research Center, Legal Medicine Organization, Kerman, Iran

4 Pathology and Stem Cells Research Center, Kerman Medical School, Kerman University of Medical Sciences, Kerman, Iran.

5 Research Center for Modeling in Health, Institute for Futures Studies in Health, Kerman University of Medical Sciences, Kerman, Iran

6 Infectious and Internal Medicine Department, Afzalipour Hospital, Kerman University of Medical Science, Kerman, Iran


Background & Objective: Since December 2019 in Wuhan, China there is a new form of pneumonia and after expansion in other countries, World Health Organization (WHO) called it Coronavirus Disease 2019 (COVID-19). Since the clinical laboratory findings have played an important role in the progression of the disease, this study aimed to evaluate the laboratory findings in COVID-19 patients (before vaccination).
Methods: In this case-control study that was conducted from February to August 2020; the laboratory test status in 101 positive COVID-19 patients was evaluated and compared with 101 healthy individuals.
Results: The results of our study showed that 21% of patients had low WBC, 24.75% low RBC, 37.62%, low Hb, 18.81% with low HCT, 29.7%, low Plt, 41.58% had High PT, 71.29% high CRP, 17.82% high urea, 11.88% high CR, 15.84% high LDH, 10.89% low sodium, 14.75% low potassium (K). The quantitative examination of blood factors showed that lymph%, mixed%, PLT, HCT, Hb, and RBC were higher in the control group than in the case group. While Neu%, WBC, PTT, CRP, UREA, LDH, K in the patient group were higher than in the control group.
Conclusion: According to the results of the study, it can be concluded that in the clinical treatment of COVID-19 patients, much attention should be paid to the laboratory indicators to identify and intervene early in critically ill patients.


Main Subjects

  1. Okba N, Müller MA, Li W, et al. Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients. Emerg Infect Dis. 2020;26(7):1478-88. [DOI:10.3201/eid2607.200841] [PMID] [PMCID]
  2. Adhikari S. P., Meng S., Wu Y. J., Mao Y. P., Ye R. X., Wang Q. Z., et al. . (2020). Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Povert. 9, e29. [DOI:10.1186/s40249-020-00646-x] [PMID] [PMCID]
  3. Chen Y., Liu Q., Guo D. (2020). Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 92, 2249. [DOI:10.1002/jmv.26234] [PMID] [PMCID]
  4. World Health Organization. (‎2020)‎. Surveillance case definitions for human infection with novel coronavirus (‎nCoV)‎, interim guidance, 15 January 2020. World Health Organization. License: CC BY-NC-SA 3.0 IGO.
  5. Liu P, Chen W, Chen JP. Viral metagenomics revealed Sendai virus and coronavirus infection of Malayan pangolins (Manis javanica). Viruses. 2019;11(11):979. [DOI:10.3390/v11110979]
  6. Wu, F., Zhao, S., Yu, B., Chen, Y. M., Wang, W., Song, Z. G., et al. A new coronavirus associated with human respiratory disease in China. Nature. 2020; 579(7798), 265-9. [DOI:10.1038/s41586-020-2008-3] [PMID] [PMCID]
  7. Zhou Y, Wang H, Zheng S. Lei. ZZ,” Advances in IEEE. 2020;802:1269-73.
  8. Ji W., Wang W., Zhao X. Cross-species transmission of the newly identified coronavirus 2019-nCoV. J Med Virol. 2020;92:433-40. [DOI:10.1002/jmv.25682] [PMID] [PMCID]
  9. Benvenuto D, Giovanetti M, Ciccozzi A, Spoto S, Angeletti S, Ciccozzi M. The 2019-new coronavirus epidemic: evidence for virus evolution. J Med Virol. 2020; 92:455-9. [DOI:10.1002/jmv.25688] [PMID] [PMCID]
  10. Poon LLM, Peiris M. Emergence of a novel human coronavirus threatening human health. Nat Med. 2020;26:317-9. [DOI:10.1038/s41591-020-0796-5] [PMID] [PMCID]
  11. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41(2):145-51.
  12. (access:March,01,2020)
  13. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. (2020) 382(13):1199-207. [DOI:10.1056/NEJMoa2001316] [PMID] [PMCID]
  14. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. [PMID] [PMCID] [DOI:10.1056/NEJMoa2002032]  
  15. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The lancet. 2020;395(10229):1054-62. [DOI:10.1016/S0140-6736(20)30566-3] [PMID]
  16. Chen M, Fan Y, Wu X, Zhang L, Guo T, Deng K, et al. Clinical characteristics and risk factors for fatal outcome in patients with 2019-coronavirus infected disease (COVID-19) in Wuhan, China. Lancet. 2020;395:1054-62.
  17. Jin JM, Bai P, He W, Wu F, Liu XF, Han DM, et al. Gender differences in patients with COVID-19: focus on severity and mortality. Front Public Health. 2020;8:152. [PMID] [PMCID] [DOI:10.3389/fpubh.2020.00152]
  18. Chong YP, Song JY, Seo YB, Choi J-P, Shin H-S, Rapid Response T. Antiviral Treatment Guidelines for Middle East Respiratory Syndrome. Infect Chemother. 2015;47(3):212-22. [DOI:10.3947/ic.2015.47.3.212] [PMID] [PMCID]
  19. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W, Tian DS. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clini Infect Dis. 2020;71(15):762-8. [DOI:10.1093/cid/ciaa248] [PMID] [PMCID]
  20. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. [DOI:10.1016/S0140-6736(20)30183-5] [PMID]
  21. Lippi G.; Plebani M. The critical role of laboratory medicine during coronavirus disease 2019 (COVID-19) and other viral outbreaks. Clin Chem Lab Med. 2020, 58, 1063-9. [DOI:10.1515/cclm-2020-0240] [PMID]
  22. Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan. China JAMA Intern Med. 2020;180:934-43. [PMID] [PMCID] [DOI:10.1001/jamainternmed.2020.0994]
  23. Chen R, Sang L, Jiang M, Yang Z, Jia N, Fu W, et al. Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China. J Allergy Clin Immunol. 2020;146(1):89-100. [PMID] [PMCID] [DOI:10.1016/j.jaci.2020.05.003]
  24. He Z, Zhao C, Dong Q, Zhuang H, Song S, Peng G, et al. Effects of Severe Acute Respiratory Syndrome (Sars) Coronavirus Infection on Peripheral Blood Lymphocytes and Their Subsets. Int J Infect Dis. 2005; 9(6):323-30. [DOI:10.1016/j.ijid.2004.07.014] [PMID] [PMCID]
  25. Fan BE, Chong VCL, Chan SSW, Lim G. H, Lim K. G. E, Tan GB, et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol (2020) 95:E131-4. [DOI:10.1002/ajh.25774]
  26. Badal S., Bajgain K.T., Badal S., Thapa R., Bajgain B.B., Santana M.J. Prevalence, clinical characteristics, and outcomes of pediatric COVID-19: A systematic review and meta-analysis. J. Clin. Virol. 2021;135:104715. [DOI:10.1016/j.jcv.2020.104715] [PMID] [PMCID]
  27. Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet (2020) 395(10223):470-3. [DOI:10.1016/S0140-6736(20)30185-9] [PMID]
  28. Tan L, Wang Q, Zhang D, Ding J, Huang Q, Tang YQ, et al. Lymphopenia predicts disease severity of COVID-19: A descriptive and predictive study. Signal Transduct Target Ther (2020) 5(1):33. [DOI:10.1038/s41392-020-0148-4] [PMID] [PMCID]
  29. Rahimzadeh G, Ekrami Noghabi M, Kadkhodaei Elyaderani F, Navaeifar M R, Enayati A A, Manafi Anari A, et al . COVID-19 Infection in Iranian Children: A Case Series of 9 Patients. J. Pediatr. Rev 2020;8(2):139-144 [DOI:10.32598/jpr.8.2.139]
  30. Ma Y, Pei S, Shaman J, Dubrow R, Chen K. Role of meteorological factors in the transmission of SARS-CoV-2 in the United States. Nat Commun. 2021;12(1):3602. [DOI:10.1038/s41467-021-23866-7] [PMID] [PMCID]
  31. de Freitas TBC, Belo RCT, Siebra SMDS, Medeiros AM, de Brito TS, et al. Quarantine, physical distancing and social isolation measures in individuals potentially exposed to SARS-CoV-2 in community settings and health services: a scoping review. Nepal J Epidemiol. 2022 Jun 30;12(2):1182-202. [PMID] [PMCID] [DOI:10.3126/nje.v12i2.43838]
  32. Chen B, Liang H, Yuan X, Hu Y, Xu M, Zhao Y, et al. Roles of meteorological conditions in COVID-19 transmission on a worldwide scale (preprint). [DOI:10.1101/2020.03.16.20037168]
  33. Wang M, Jiang A, Gong L, Lina L, Wenbin G, Chuyi L, et al. Temperature Significantly Change COVID -19 Transmission in 429 cities. medRxiv 2020.02.22.20025791; [DOI:10.1101/2020.02.22.20025791]
  34. Oliveiros, Bárbara. (2021). Role of Temperature and Humidity in the Modulation of the Doubling Time of Covid-19 Cases. J Biogen Sci Res. 8. [DOI:10.46718/JBGSR.2021.08.000199]
  35. Wu C, Zheng S, Chen Y, Zheng M. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCoV, in the nasal tissue. MedRxiv. 2020 Feb 13:2020-02.
  36. Xu H, Zhong L, Deng J, Peng J, Dan H, Zeng X, Li T, Chen Q. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12(1):1-5. [DOI:10.1038/s41368-020-0074-x] [PMID] [PMCID]
  37. Liao YC, Liang WG, Chen FW, Hsu JH, Yang JJ, Chang MS. IL-19 induces production of IL-6 and TNF-alpha and results in cell apoptosis through TNF-alpha. J Immunol. 2002;169(8):4288-97. [DOI:10.4049/jimmunol.169.8.4288] [PMID]
  38. Aggarwal S, Gollapudi S, Gupta S. Increased TNF-alpha-induced apoptosis in lymphocytes from aged humans: changes in TNF-alpha receptor expression and activation of caspases. J Immunol (1999) 162:2154-61. [DOI:10.4049/jimmunol.162.4.2154] [PMID]
  39. Panesar N. What caused lymphopenia in SARS and how reliable is the lymphokine status in glucocorticoid-treated patients? Med Hypotheses. 2008;71(2):298-301. [PMID] [PMCID] [DOI:10.1016/j.mehy.2008.03.019]
  40. Henry BM, Lippi G, Plebani M. Laboratory abnormalities in children with novel coronavirus disease 2019. Clin Chem Lab Med 2020;58:1135-8. [DOI:10.1515/cclm-2020-0272] [PMID]
  41. Liu Y, Du X, Chen J, Jin Y, Peng L, Wang HHX, et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J Infect. 2020;81:e6-12. [DOI:10.1016/j.jinf.2020.04.002] [PMID] [PMCID]
  42. Liao D, Zhou F, Luo L, Xu M, Wang H, Xia J, et al. Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study. The Lancet Haematology. 2020 Sep 1;7(9):e671-8. [DOI:10.1016/S2352-3026(20)30217-9] [PMID]
  43. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb Haemost. 2020;18(4):844-7. [DOI:10.1111/jth.14768] [PMID] [PMCID]